PD Dr. rer. nat. Daniel Mertens

Name, Academic Title:	Daniel Mertens, PD Dr. rer. nat.
Date and Place of Birth:	24.11.1969; Hechingen, Germany
Sex:	Male
Office Address:	Department of Internal Medicine III, Ulm University, Albert-Einstein-Allee 23, 89081 Ulm, Germany, and Cooperation Unit "Mechanisms of Leukemogenesis", DKFZ Heidelberg, Im Neuenheimer Feld 280, 69120 Heidelberg
Phone:	+49-731-500-45870
Fax:	+49-731-500-45845
E-Mail:	daniel.mertens@uniklinik-ulm.de; d.mertens@dkfz.de
Current Position:	Scientist, Department of Internal Medicine III, Ulm University
Children:	Two (6 and 9 years)

2. University Education

1995-1996	Diploma in Developmental Genetics, Tübingen
1990-1994	Biochemistry at the Eberhard-Karls University, Tübingen

3. Academic Degrees

2011	Venia Legendi (*Privatdozent*), Molecular Medicine, University Ulm
2001	Doctoral Thesis (*Dr. rer. nat.*), Deutsches Krebsforschungs-zentrum, Heidelberg, Advisor: Prof. Peter Lichter

4. Professional Experience

Since 2010	Head of the Cooperation Unit "Mechanisms of Leukemogenesis", DKFZ and University Ulm
Since 10/2006	Junior Group Leader at the DKFZ in Heidelberg.
09/2006-2010	Head of the Max-Eder-Group, University Hospital Ulm.
08/2001-10/2006	Supervision of a project group at the DKFZ
05/1996-09/1996	Completion of the INRA project at the Department for Developmental Biology, Tübingen.
06/1996	Gene expression analyses of *GNOM*-mutants with filter-DNA-arrays at the Laboratoire de Biologie Cellulaire (INRA), Paris
10/1996-05/1999	Functional analyses of the cell-cycle-associated phosphatase cdc25B using tet-inducible expression systems in cell culture in the department of Prof. Harald zur Hausen, DKFZ, Heidelberg.

5. Honors

06/2002	Leukemia Research Award, Franziska-Kolb Foundation, University of Ulm

6. Publications and Patents

1. Bhattacharya N, Diener S, Idler IS, Barth TF, Rauen J, Habermann A, Zenz T, Möller P, Döhner H, Stilgenbauer S, Mertens D. Non-malignant B cells and chronic lymphocytic leukemia cells induce a pro-survival phenotype in CD14(+) cells from peripheral blood. **Leukemia**. 2011;25(4):722-726,
2. Bhattacharya N, Diener S, Idler I, Rauen J, Häbe S, Busch H, Habermann A, Döhner H, Stilgenbauer S, Mertens D. Nurse-like cells show deregulated expression of genes involved in immunocompetence. **Br J Haematol**. 2011;154:3:349-356.
3. Zenz T, Mertens D, Kuppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. **Nat Rev Cancer**. 2010;10(1):37-50.

4. Bhattacharya N, Sarno A, Idler I, Nothing M, Zenz T, Döhner H, Stilgenbauer S, Mertens D. High-throughput detection of NF-κB activity using a robust and sensitive oligo-based chemiluminescent ELISA. **Int J Cancer**. 2010;127:404-411.
5. Mertens D, Wolf S, Tschuch C, Mund C, Kienle D, Ohl S, Schroeter P, Lyko F, Döhner H, Stilgenbauer S, Lichter P. Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. **Proc Natl Acad Sci U S A**. 2006;103(20): 7741-6.

Patent

- Joos S, Lichter P, Mertens D, Pscherer A, Wolf S: „Diagnosis and therapy of cell proliferative disorders characterized by resistance to TRAIL induced apoptosis“, International Patent. 2005; P 617 PCT / EZ